Press Release - May 09, 2022 Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022
LONDON, ONTARIO – May 9, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions, to be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
Abstract 306-OR: Modified Approach for Improved Islet Allotransplantation into Prevascularized Sernova Cell PouchTM Device: Preliminary Results of the Phase I/II Clinical Trial at University of Chicago
Abstract Session: Islet Transplantation —Basic Science Session Date/Time: Monday, June 6, 2022 at 2:15 PM – 4:15 PM CT Presentation Time: 3:15-3:30 PM CT Authors: Bachul PJ, Perez-Guetierrez A, Ling-jia Wang, Golab K, Basto L, Perea L, Tibudan M, Braden J, Thomas C, Philipson L, Barth R, Fung JJ, Witkowski P
Sernova will disclose additional information about the presentation at the time of the conference in alignment with the American Diabetes Association’s abstract embargo policies.